Skip to main content
European Commission logo print header

Tissue-derived acellular micro-scaffold technology reducing or eliminating diabetics’ dependence on insulin therapy

Ziel

Betalin’s mission is to provide a tissue-derived acellular micro-scaffold that will extend the life and the insulin-producing
performance of transplanted beta cells in order to reduce or eliminate the dependence of some diabetics on insulin therapy.
Type 1 Diabetes is a chronic disease that results from the autoimmune destruction of the insulin-producing beta cells in the
pancreas. Its cause is still uncertain and there is no known way to prevent its onset. With~70,000 new cases diagnosed
each year, it is estimated that ~17 mn people worldwide are afflicted with T1DM. In the US alone, T1DM results in $14.4 bn
in medical costs and lost income annually. Type 1 diabetics face a lifetime regime of insulin therapy and very careful lifestyle
management in an attempt to mitigate the long-term complications associated with T1DM such as cardiovascular disease,
damage to the eyes, kidneys and nerves, and premature death. In recent years islet transplantation has been researched as
a treatment for T1DM. The procedure involves injecting millions of islets (the pancreatic cell clusters that “house” the
insulinproducing
beta cells) harvested from cadavers, followed by immunosuppression therapy. Islet transplantation is a promising
approach but the naked islets are very unstable: they must be transplanted almost immediately after harvesting and up to
80% of the transplanted islets stop functioning within 24hrs. The result is that, after five years, less than 10% of the
recipients are free of daily insulin treatment. Betalin’s technology is based on the premise that in order for beta cells to
function properly it is necessary to provide an appropriate stromal (connective tissue) micro-environment. The proprietary
platform technology is a method to prepare acellular organ-derived micro-scaffolds that preserve the architecture and the
basic composition of organ stroma and ensure that no seeded cell will be more than 150 microns from a source of nutrients
and gases.

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2016-2017

Koordinator

BETALIN THERAPEUTICS LTD
Netto-EU-Beitrag
€ 50 000,00
Adresse
3 menachem begin
5268101 Ramat gam
Israel

Auf der Karte ansehen

KMU

Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen).

Ja
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Weitere Finanzmittel
€ 21 429,00